Navigation Links
Carl Marks Seeds New Healthcare Fund Through Strategic Partnership With BlueStar Capital Management
Date:11/28/2007

NEW YORK, Nov. 28 /PRNewswire/ -- Carl Marks & Co. LP has partnered with BlueStar Capital Management LP to launch the BlueStar CM Life Sciences Focus Fund LP. The partnership also gives Carl Marks a stake in BlueStar Capital Management, which invests in healthcare hedge funds, and an increased presence in the healthcare investment sector.

The new Focus Fund invests in highly concentrated portfolios which are long and short public healthcare equities, in both managed accounts and limited partnerships.

"We feel the healthcare market provides attractive and solid investment opportunities," said Mark Claster, president of Carl Marks & Co., "and BlueStar Capital Management's long experience with healthcare hedge funds makes this the perfect strategic relationship for our investment interests."

Carl Marks's Andrew Boas will join BlueStar Capital's Advisory Board. Boas is a principal of Carl Marks Management Company.

Jonathan Lach of BlueStar Capital said, "The Focus Fund is invested in the best ideas of some of the best investors in public healthcare equities, a sector that is rich with investment opportunity. We are very pleased to be partnering with Carl Marks, an extremely fine firm with much to contribute to our mutual success."

About Carl Marks & Co.

Founded in 1925, Carl Marks began as a dealer of foreign securities in the United States. The company has diversified into a multi-faceted investment and advisory services firm offering a range of specialized services, including corporate revitalization and investment banking, distressed securities, private equity, real estate and asset management. For more information, visit http://www.carlmarks.com.

About BlueStar Capital Management LP

BlueStar Capital Management LP invests primarily in healthcare hedge funds and provides investment and consulting services for its clients in this dynamic investment sector. The firm manages BlueStar Life Sciences LP, a healthcare sector of funds, and BlueStar CM Life Sciences Focus Fund LP, which invests in a more concentrated manner in the healthcare sector. Additional information about BlueStar Capital Management is available at http://www.bluestar-capital.com.


'/>"/>
SOURCE Carl Marks & Co. LP
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Kendle Marks 10th Anniversary as Public Company With NASDAQ Opening Bell Ceremony and Investor Day Event
2. Social Network for Scientists Marks Ten Years Online
3. Diplomat Specialty Pharmacy Health Services Division Achieves High Marks in Pilot Program for Chronic Kidney Disease Management
4. Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results
5. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
6. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
7. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
8. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
9. InterCure and Omron Healthcare (UK) Ltd. Announce Marketing Collaboration for Hypertension Market in United Kingdom
10. Apria Healthcare Chooses Masimo SET Pulse Oximetry for Use in the Companys Home Health Care Business
11. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created ... services and solutions to the healthcare market. The company's primary focus is on ... sales and marketing strategies that are necessary to help companies efficiently bring their ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) is ... treatments and faster cures for prostate cancer. Members of the Class of 2016 ... countries. Read More About the Class of 2016 PCF ... ... ...
Breaking Biology Technology:
(Date:5/24/2016)... , May 24, 2016 Ampronix facilitates superior patient care by providing unparalleled ... medical LCD display is the latest premium product recently added to the range of ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC , ... announced the opening of an IoT Center of Excellence ... and expand the development of embedded iris biometric applications. ... level of convenience and security with unmatched biometric accuracy, ... identity aside from DNA. EyeLock,s platform uses video technology ...
(Date:5/9/2016)... May 9, 2016 Elevay is ... to expanding freedom for high net worth professionals seeking ... today,s globally connected world, there is still no substitute ... ever duplicate sealing your deal with a firm handshake. ... by taking advantage of citizenship via investment programs like ...
Breaking Biology News(10 mins):